This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis appears to have been conducted on an intention to treat basis. The rate of relapse requiring hospital admission and the rate of community-treated relapse were calculated, and confidence intervals were estimated using a method for proportions. Episodes of oral corticosteroid prescription were identified from the University of Dundee's Medicines Monitoring Unit prescribing database using a record linkage method. It was assumed that each corticosteroid prescription represented a community-treated relapse. Prescriptions associated with bronchodilators were assumed to be for asthma and therefore were excluded. A previous study of relapse frequency in secondary progressive multiple sclerosis showed a reduction in relapse from the first year after onset to the second year. These data were not used in the model since the study cohort contained people who had had the disease for more than two years and were likely to have a lower relapse rate. A recent survey of British neurologists showed that 47% of neurologists treated at least half of the multiple sclerosis relapses with corticosteroids. Therefore it was assumed that, for every relapse treated (hospital or community), there was a further untreated relapse. Clinical outcomes were relapse rate and the percentage of patients who became wheelchair dependent.
Effectiveness results

(18%) of the cohort became wheelchair dependent within 36 months of follow-up.
The number needed to treat (NNT) for 30 months to postpone wheelchair dependence in one person by nine months was estimated to be 18 (95% CI: 5 -26).
4 (24%) of the neurology subset became wheelchair dependent.
The number needed to treat to postpone wheelchair dependence by nine months in the neurology subset was 14.
32 admissions were identified for treatment of relapse in the 36 month follow-up period, generating a rate of 0.08 (95% CI: 0.06 -0.11) per patient-year. 56 discrete corticosteroid episodes were identified in 21 people, but 3 people had concomitant bronchodilators prescribed and were excluded, and one oral steroid prescription preceded an admission to hospital for relapse by 15 days.
The rate of community treated relapses was 0.15 (95% CI: 0.11 -0.18) per patient-year.
The neurology subset experienced 7 hospital admissions for relapse and 4 community corticosteroid prescriptions in the 30 months to the end of December 1995. This suggested an estimated 11 untreated relapses.
Three years after the end of follow-up (Spring 1998), a postal survey of people with multiple sclerosis in Tayside was conducted to create a baseline from which to estimate the effect of interferon beta. The EuroQOL and a postal ambulation scale (based on the scale of McAlpine and Compston) were administered. The number of quality-adjusted life years (QALYs) gained by postponing wheelchair dependence by 9 months was equal to the change in EQ-5D value associated with a change in postal ambulation scale score from 4 to 5 multiplied by 0.75 years. The number of QALYs gained by preventing a one-month hospital relapse was equal to the change in EQ-5D value associated with a change in postal ambulation scale score from 4 to 5 multiplied by 0.083 years. For each community-treated relapse and untreated relapse, postal ambulation scale scores changed from 3 to 4 for one month. It was assumed that 40% of QALYs were gained in years 1 and 2 and 20% were gained in the final six months of the 30-month programme. A discount rate of 6% was applied to QALYs gained in years 2 and 3.
Direct costs
Costs saved by delaying the time to wheelchair dependence by nine months were estimated from a cost analysis based on information from 672 members of the Multiple Sclerosis Society of Great Britain and Northern Ireland. Resource utilisation data were valued using data from local NHS trust finance directories (personal communication). Fixed and non-fixed costs were differentiated when costing relapses, but this was not possible for wheelchair dependence as the study lacked information. It was assumed that each community-treated relapse required 20 minutes consultation with a general practitioner (GP) and that untreated relapses did not incur health service costs (although GP costs may have been incurred). Corticosteroid costs were taken from the 1995 British National Formulary. All costs were adjusted to 1995 using the Department of Health hospital and community health services price index. Treatment costs were discounted at 6% in the second and third years.
Statistical analysis of costs
Not stated.
Indirect Costs
Indirect costs were not included.
Currency
UK pounds Sterling ().
Sensitivity analysis
A series of one-way sensitivity analyses was performed to explore the effects of: increasing the cost of each additional nine months of wheelchair dependence (taking account of the societal perspective), changes in the unit cost of interferon beta-1b, changes in the number of, and discount rates applied to, QALYs gained, and assuming that the relative risk reduction in hospital admission and corticosteroid use was 31% (not 12% or 21%).
Also a threshold analysis was performed to determine the changes required in model variables to breach the thresholds of 10,000, 20,000, 30,000 and 50,000 per QALY gained.
Estimated benefits used in the economic analysis
Treatment of 18 members of the population cohort and 14 members of the neurology subset for 30 months would result in a gain of 0.397 and 0.357 QALYs respectively.
